We Ran Our Own Study.

Over the past few years, GLP 1 medications like semaglutide have changed what is possible in obesity care. For many people, these treatments have provided a path to meaningful weight loss and better long term health. But while the science has advanced quickly, access has not kept up. Many patients struggle with shortages, unpredictable insurance decisions, and high pharmacy costs. In this environment, even the most effective medication can fall short if people cannot get it consistently.

At Mochi Health, we have spent years listening to patients, solving access challenges, and watching the real life ups and downs of GLP 1 care. We also realized that one important question was not being answered clearly anywhere else: how well does compounded semaglutide perform in real world settings when compared with branded Wegovy?

Because no large scale study existed, we decided to conduct our own.

Our clinical research team analyzed thousands of patient experiences within our telemedicine program to understand whether compounded semaglutide plus B12 could support similar progress and help more people stay on treatment. While the scientific paper presents the formal results, the larger story is about what this means for the future of access, affordability, and patient choice.

This article explains why we did the study, what we learned, and why compounded medications may play a major role in expanding access to treatments across the country.

Why Mochi Decided To Run Its Own Study

As shortages of Wegovy and similar GLP 1 drugs spread across the United States, a lot of people suddenly found themselves without access to their medication. Pharmacies were backordered. Insurance plans were inconsistent. Patients were frustrated, losing progress, and feeling anxious about their care.

Mochi was seeing this every day in our program. People who were motivated and doing everything right were being held back by supply problems and high costs. Providers were spending hours trying to locate doses. Many patients were forced to pause treatment even though it was helping them.

Compounded medications entered the conversation because they offered a way to keep treatment going when branded semaglutide was unavailable. But they also raised understandable questions. Patients wanted to know whether compounded semaglutide was effective. They wanted to understand safety. They wanted reassurance that the medication was being prepared carefully and consistently. And no research existed at the scale needed to answer those questions confidently.

Rather than rely on assumptions, Mochi did what a responsible clinical program should do. We worked with a trusted compounding partner, and conducted one of the largest real world comparisons of Wegovy and compounded semaglutide ever performed.

This study was not about proving one product is better than another. It was about giving patients clarity. It was about understanding how these treatments behave in actual care settings. Most importantly, it was about making sure people have safe, reachable, and reliable options.

What Mochi Found When Comparing Wegovy and Compounded Semaglutide

While the study contains detailed analysis, the bigger picture can be described without scientific language. In everyday terms, the people using compounded semaglutide plus B12 in the Mochi program lost weight at about the same pace as people using branded Wegovy. Their progress looked very similar across the early months of treatment. The pattern held steady through the typical six month mark when many patients reach their first major milestones.

Another important finding was that more patients stayed on the compounded medication. Many people said they felt more confident because they knew their refills would be available. Others appreciated that the cost was more predictable. Because compounded semaglutide was prepared by one consistent partner pharmacy, supply did not fluctuate the way it did with retail branded options.

This difference in treatment continuity matters. The more consistently people can stay on their medication, the better chance they have of reaching and maintaining their weight loss results. Our study showed that compounded medications can make this easier in real world settings. Compounded medications are cheaper and more accessible for more people.

Why These Findings Matter for Patient Access

The most important message from the Mochi study is not just that compounded semaglutide supported similar weight progress. The larger meaning is that compounded medications can help people stay on track when the rest of the healthcare system feels unpredictable.

For years, obesity care has struggled with barriers that have nothing to do with medical science. People who qualify for treatment often wait months to get it. Others cannot afford the brand name version. Some lose access halfway through their journey because insurance rules change.

These problems create a kind of instability that holds patients back. They interrupt progress. They undermine motivation. They make treatment feel fragile.

Compounded medications, when prepared with high quality standards, can offer a smoother experience. They can help individuals keep moving forward even when branded medications are out of stock. They can reduce the emotional stress of wondering whether the next refill will be available. They can make treatment more predictable, which is one of the most important ingredients in long term success.

The Mochi study showed what happens when compounded medications are used thoughtfully and consistently: People stay engaged. They feel supported. They feel confident in their plan. And for many, that is what makes the difference between starting treatment and actually succeeding with it.

How This Could Change the Future of Obesity Care

The growing popularity of GLP 1 medications has revealed a basic truth. Our system is not yet equipped to make highly effective treatments accessible to everyone who needs them. The supply chain is fragile. Costs vary dramatically. Coverage rules change frequently. Millions of people who qualify for GLP 1s still cannot get them.

Compounded medications are not a replacement for FDA approved treatments, but they can strengthen the system in important ways. They can reduce pressure on retail pharmacies. They can provide alternatives when shortages occur. They can help lower costs for patients who do not have insurance coverage. They can make treatment more resilient to the unpredictable swings that have defined the GLP 1 landscape so far.

If more real world research like Mochi’s continues, and if compounding standards and oversight become even stronger, compounded medications could play a long term role in improving access not only in obesity care but in other therapeutic areas as well. They could help create a more flexible healthcare system that supports patients through real challenges instead of leaving them stuck when supply runs low.

At Mochi, we see this future as both promising and necessary. The demand for obesity care will continue to grow. People deserve treatments that are safe, steady, and reachable. Compounded medications, studied carefully and used responsibly, can help build that future.

Mochi’s Commitment to Responsible Compounding

One of the reasons Mochi was able to successfully study compounded semaglutide is that we took a structured, cautious approach. We partnered with a single trusted compounding pharmacy so that every patient received the same formulation. We monitored outcomes closely. We compared thousands of data points collected through normal care. We ensured all information was de identified and securely analyzed.

This level of consistency is unusual in real world compounding research, and it is why the study offers such clear insights. It also reflects how seriously Mochi approaches patient safety. The quality of compounded medications can vary widely. That is why at Mochi we work hard to ensure our healthcare partners are reliable and follow the highest standards.

We believe in transparency and results.

What Patients Should Know if They Are Considering Compounded Semaglutide

Patients often want to know whether compounded semaglutide is a good fit for them. The answer depends on their history, their goals, and their access to branded options. For many people, compounded semaglutide is helpful because it offers a more predictable experience. They can start sooner. They can avoid gaps. They can focus on their health rather than the pharmacy supply chain.

It is important to remember that compounded medications are not FDA approved and should be used only under the supervision of a qualified clinician. But when they are prepared correctly and prescribed thoughtfully, they can support progress in meaningful ways.

At Mochi, patients also benefit from nutrition guidance, ongoing support, and a team familiar with both branded and compounded treatments. Many people appreciate having options instead of being limited by whatever happens to be in stock.

Mochi’s real world study offers more than a comparison of two medications. It highlights what is possible when access, consistency, and patient support are treated as essential parts of healthcare rather than afterthoughts. Compounded semaglutide is not meant to replace FDA approved options, but our findings show that, when prepared responsibly and paired with thoughtful clinical oversight, it can help people stay on treatment, maintain momentum, and feel more in control of their care. In a landscape where many patients still struggle to obtain GLP 1 medications, compounded options give people a dependable way forward and point toward a future where life changing treatments are not limited by supply or cost. As demand for obesity care continues to grow, Mochi is committed to leading with transparency, high standards, and real data so that every patient can access the tools they need to reach their goals.

Check Your Eligibility

If you are interested in GLP 1 treatment or want to learn whether compounded semaglutide is an option for you, you can start by completing Mochi’s simple eligibility questionnaire. It only takes a few minutes and helps our clinical team understand your goals, medical history, and the safest path forward. Every patient receives personalized guidance, clear information about medication options, and support throughout their care. You can begin your eligibility check today and take the first step toward consistent, accessible, and dependable obesity treatment with Mochi.

FAQs

What is the purpose of Mochi’s study
The study was designed to understand how compounded semaglutide performs in real life care compared to Wegovy. Since no large scale real world research existed, Mochi conducted its own analysis to help patients make informed decisions.

Is compounded semaglutide the same as Wegovy?
They are not the same. Wegovy is FDA approved semaglutide. Compounded semaglutide is prepared by licensed pharmacies when a patient cannot access the approved product. Mochi used a single standardized compounding partner to make sure the formulation was consistent.

Why did more people stay on compounded semaglutide?
Many patients found it easier to access, more affordable, and more predictable. These practical benefits made it less likely that people would have to pause treatment due to supply or cost issues.

Does the study prove that compounded semaglutide is safe?
he study found that side effect patterns looked similar to Wegovy within the limits of routine care. However, larger safety studies are still needed. Mochi continues to monitor outcomes closely.

How does compounded semaglutide help with access?
It helps people avoid delays, shortages, and unpredictable refill issues. It also offers a lower cost option for patients who do not have coverage for branded medications.

Will compounded medications play a bigger role in obesity care?
Possibly. If more research, oversight, and standardization continue, compounded medications could support broader access and reduce many barriers that patients face today.

Should I choose compounded semaglutide?
Your provider can help you decide. For people who cannot access Wegovy or who want a more predictable experience, compounded semaglutide may be a helpful option under clinical supervision.